New Phase II data show vast majority of patients experiencing no relapses or disability progression
Birajeev is a seasoned Supply Chain leader with an experience of 23 years
ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the USFDA
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Phase 3 study results will form the basis for future discussions with global regulatory authorities
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
Subscribe To Our Newsletter & Stay Updated
